

PATENT
5148US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ronald Vogels et al.

Serial No.: To be assigned

Filed: November 15, 2001

For: COMPLEMENTING CELL LINES

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 5148US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: _____

Date of Deposit with USPS: November 15, 2001

Person making Deposit: _____

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the referenced patent application as follows:

IN THE CLAIMS:

Please cancel claims 23 through 32, 41 and 42 without prejudice or disclaimer. For the convenience of the Office, all pending claims are set forth herein.

1. A packaging cell line capable of complementing recombinant adenovirus based on a serotype from subgroup B.

2. The packaging cell line of claim 1 wherein said serotype from subgroup B is adenovirus type 35.

3. (Amended) The packaging cell line of claim 2, wherein said packaging cell line is derived from primary, diploid human cells, or derivatives thereof, said primary, diploid human cells or derivatives thereof having been transformed by adenovirus E1 coding sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, said adenovirus E1 coding sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins.

4. The packaging cell line of claim 3 wherein the primary, diploid human cells, or derivatives thereof have been selected from the group consisting of primary human retinoblasts, primary human embryonic kidney cells and primary human amniocytes.

5. (Amended) The packaging cell line of claim 4, wherein the primary, diploid human cells, or derivatives thereof have been transfected with an adenovirus E1A coding sequence to induce unlimited proliferation.

6. The packaging cell line of claim 5 wherein said packaging cell line further comprises an E1B coding sequence.

7. (Amended) The packaging cell line of claim 4, wherein the primary, diploid human cells, or derivatives thereof have been transformed by expression of adenovirus E1 proteins of a subgroup other than subgroup C.

8. The packaging cell line of claim 7 wherein the subgroup other than subgroup C is subgroup B.

9. The packaging cell line of claim 8, wherein said adenovirus E1 proteins are derived from adenovirus type 35.

10. (Amended) The packaging cell line of claim 4, wherein the primary, diploid human cells or derivatives thereof have been transformed with a chimeric adenovirus E1 construct comprising part of a first adenovirus E1 coding sequence of a first adenovirus serotype that enables efficient transformation of primary human cells or derivatives thereof; and part of a second adenovirus E1 coding sequence of a second adenovirus serotype, wherein said second adenovirus E1 coding sequence provides the serotype-specific adenovirus E1B function(s) that enable(s) efficient propagation of recombinant adenovirus E1-deleted viruses of said second adenovirus serotype.

11. The packaging cell line of claim 10 wherein said first adenovirus serotype is a subgroup C adenovirus and said second adenovirus serotype is a subgroup B adenovirus, more particular adenovirus type 35.

12. The packaging cell line of claim 10 wherein E1A coding sequence and at least part of the E1B-21K coding sequence are derived from a subgroup C adenovirus, and the E1B-55K coding sequence as far as not overlapping with the 21K coding sequence is derived from a subgroup B adenovirus.

13. The packaging cell line of claim 12 wherein said subgroup B adenovirus is adenovirus type 35.

14. The packaging cell line of claim 10 wherein all E1 coding sequences are derived from a subgroup C adenovirus, except for at least a part of the E1B-55K coding sequence that is necessary

for serotype-specific complementation of an alternative adenovirus serotype, said E1B coding sequence being derived from said alternative adenovirus serotype.

15. The packaging cell line of claim 6, wherein said packaging cell line comprises bovine adenovirus E1B-55K.

16. The packaging cell line of claim 15, wherein said complementing recombinant adenovirus is derived from a bovine adenovirus.

17. (Amended) The packaging cell line of claim 4, wherein the primary, diploid human cells or derivatives thereof have been transformed by adenovirus E1 coding sequences located on two separate DNA molecules wherein the first DNA molecule carries at least part of the E1 coding sequences of the serotype enabling efficient transformation and the second DNA molecule carries at least part of the sequences necessary for serotype-specific complementation.

18. The packaging cell line of claim 4 wherein said derivative cells are PER.C6 (ECACC deposit number 96022940) which further comprise an Ad35-E1 region integrated into their genome, and wherein said Ad35-E1 region is present in a functional expression cassette.

19. The packaging cell line of claim 18 wherein said Ad35-E1 region does not contain sequences overlapping with sequences present in an associated recombinant viral vector.

20. (Amended) The packaging cell line of claim 18, wherein said functional expression cassette comprises a heterologous promoter and a poly-adenylation signal functionally linked to said Ad35-E1 region, wherein said heterologous promoter is a human phosphoglycerate gene promoter (hPGK) and wherein said poly-adenylation signal is a hepatitis B virus poly-adenylation signal (HBV-pA).

21. The packaging cell line of claim 20 wherein said Ad35-E1 region comprises the coding regions of the E1A proteins and the E1B promoter sequence linked to E1B coding sequences up to and including the stop codon of the E1B 55K protein.

22. The packaging cell line of claim 20 wherein said Ad35-E1 region comprises nucleotide 468 up to and including nucleotide 3400 of the Ad35 wild-type sequence.

33. (Amended) The packaging cell line of claim 3, further comprising a DNA encoding at least E4-orf6 of an adenovirus of subgroup B.

34. (Amended) A process for complementing a recombinant adenovirus, said method comprising:
providing the packaging cell line of claim 3, with said recombinant adenovirus; and
culturing said cell to allow for complementation.

35. The process according to claim 34, further comprising harvesting complemented recombinant adenovirus.

36. (Amended) The process according to claim 34, wherein said recombinant adenovirus is derived from a subgroup B adenovirus.

37. The process according to claim 36, wherein said recombinant adenovirus is derived from adenovirus type 35.

38. (Amended) A recombinant adenovirus produced by the process according to claim 34.

39. The recombinant adenovirus of claim 38, further having a deletion of nucleic acid encoding at least one E1-region protein.

40. (Amended) The recombinant adenovirus of claim 38, further comprising a deletion of nucleic acid encoding at least one E3-region protein and/or at least one E4-region protein.

Please add the following new claims:


43. (New) The packaging cell line of claim 10, wherein said packaging cell line comprises bovine adenovirus E1B-55K.

44. (New) The packaging cell line of claim 43, wherein said complementing recombinant adenovirus is derived from a bovine adenovirus.

Remarks

The application is to be amended without prejudice or disclaimer as previously set forth, which should not be viewed as narrowing or limiting the claims. The amendments are sought to conform the application to a form more consistent with Office practice by, for example, removing multiple dependencies and "use" claims. Claims 23 through 32 are to be canceled without prejudice as being very similar to claims 21 through 28 generally of the parent application. It is respectfully submitted that no new matter has been added by the amendments. Should the Office determine that additional issues remain which might be resolved by a telephone conference, the Office is kindly invited to contact applicants' undersigned attorney.

Respectfully Submitted,



Allen C. Turner
Registration Number 33,041
Attorney for Applicants
TRASKBRITT, PC
P.O. Box 2550
Salt Lake City, Utah 84110
Telephone: (801) 532-1922

Date: November 15, 2001

Enclosure: Version With Markings to Show Changes Made

N:\2183\5148\preliminary amend.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. (Amended) The packaging cell line of claim [1 or] 2, wherein said packaging cell line is derived from primary, diploid human cells, or derivatives thereof, said primary, diploid human cells or derivatives thereof having been transformed by adenovirus E1 coding sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, said adenovirus E1 coding sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins.

5. (Amended) The packaging cell line of claim [3 or] 4, wherein the primary, diploid human cells, or derivatives thereof have been transfected with an adenovirus E1A coding sequence to induce unlimited proliferation.

7. (Amended) The packaging cell line of claim [3 or] 4, wherein the primary, diploid human cells, or derivatives thereof have been transformed by expression of adenovirus E1 proteins of a subgroup other than subgroup C.

10. (Amended) The packaging cell line of [claim 3 or] claim 4, wherein the primary, diploid human cells or derivatives thereof have been transformed with a chimeric adenovirus E1 construct comprising part of a first adenovirus E1 coding sequence of a first adenovirus serotype that enables efficient transformation of primary human cells or derivatives thereof; and part of a second adenovirus E1 coding sequence of a second adenovirus serotype, wherein said second adenovirus E1 coding sequence provides the serotype-specific adenovirus E1B function(s) that enable(s) efficient propagation of recombinant adenovirus E1-deleted viruses of said second adenovirus serotype.

15. (Amended) The packaging cell line of claim 6[, claim 10 or claim 14], wherein said packaging cell line comprises bovine adenovirus E1B-55K.

17. (Amended) The packaging cell line of claim [3 or] 4, wherein the primary, diploid human cells or derivatives thereof have been transformed by adenovirus E1 coding sequences located on two separate DNA molecules wherein the first DNA molecule carries at least part of the E1 coding sequences of the serotype enabling efficient transformation and the second DNA molecule carries at least part of the sequences necessary for serotype-specific complementation.

20. (Amended) The packaging cell line of claim 18 [or claim 19], wherein said functional expression cassette comprises a heterologous promoter and a poly-adenylation signal functionally linked to said Ad35-E1 region, wherein said heterologous promoter is a human phosphoglycerate gene promoter (hPGK) and wherein said poly-adenylation signal is a hepatitis B virus poly-adenylation signal (HBV-pA).

33. (Amended) The packaging cell line of [any one of claims 1 through 22, or the cell line of any one of claims 23-32] claim 3, further comprising a DNA encoding at least E4-orf6 of an adenovirus of subgroup B.

34. (Amended) A process for complementing a recombinant adenovirus, said method comprising:

providing the packaging cell line of [any one of claims 1 through 22 or the cell line of any one of claims 23 through 33] claim 3, with said recombinant adenovirus; and
culturing said cell to allow for complementation.

36. (Amended) The process according to claim 34 [or claim 35], wherein said recombinant adenovirus is derived from a subgroup B adenovirus.

38. (Amended) A recombinant adenovirus produced by the process according to [any one of claims 34 through 37] claim 34.

40. (Amended) The recombinant adenovirus of claim 38 [or claim 39], further comprising a deletion of nucleic acid encoding at least one E3-region protein and/or at least one E4-region protein.